Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.40 +1.3%	$0.41	$0.22 ▼ $1.30	$8.65M	1	4.25 million shs	506,966 shs
KLDO Kaleido Biosciences		$0.00	$0.00 ▼ $0.07	$6.39M	-0.06	11,644 shs	N/A
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	N/A
ONCS OncoSec Medical		$0.52	$0.18 ▼ $20.46	$1.26M	1.99	2.22 million shs	52.49 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+5.53%	-8.99%	+2.60%	-39.23%	-59.07%
KLDO Kaleido Biosciences	0.00%	+9,900.00%	+9,900.00%	+4,900.00%	+9,900.00%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
ONCS OncoSec Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	3.3433 of 5 stars	3.8	5.0	0.0	0.0	2.4	0.0	1.3
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	1,900.00% Upside
KLDO Kaleido Biosciences	0.00	N/A	N/A	N/A
NMTR 9 Meters Biopharma	0.00	N/A	N/A	N/A
ONCS OncoSec Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.64 per share	N/A
KLDO Kaleido Biosciences	$1.10M	0.00	N/A	N/A	N/A	NaN
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	$3.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.46	N/A	N/A	N/A	N/A	-218.88%	-177.61%	N/A
KLDO Kaleido Biosciences	N/A	-$2.24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
ONCS OncoSec Medical	-$34.18M	-$15.29	N/A	N/A	N/A	N/A	-868.29%	-160.61%	N/A

Latest ONCS, ADIL, KLDO, and NMTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	ADIL Adial Pharmaceuticals	-$0.50	-$0.34	+$0.16	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
ONCS OncoSec Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	1.99	1.99
KLDO Kaleido Biosciences	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	0.59	0.59
ONCS OncoSec Medical	N/A	0.89	0.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
KLDO Kaleido Biosciences	81.56%
NMTR 9 Meters Biopharma	22.34%
ONCS OncoSec Medical	8.69%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
KLDO Kaleido Biosciences	9.00%
NMTR 9 Meters Biopharma	2.40%
ONCS OncoSec Medical	1.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	21.62 million	20.69 million	No Data
KLDO Kaleido Biosciences	80	42.62 million	38.79 million	Not Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
ONCS OncoSec Medical	40	4.55 million	4.49 million	Not Optionable

ONCS, ADIL, KLDO, and NMTR Headlines

Recent News About These Companies

PVCT Provectus Biopharmaceuticals, Inc.

August 25, 2024 | seekingalpha.com

Is OncoSec Medical Inc (ONCSQ) Stock a Good Investment?

June 29, 2023 | aaii.comA

ONCS - OncoSec Medical Incorporated

June 24, 2023 | finance.yahoo.com

0 analysts rank ONCS stock as an Overweight

June 23, 2023 | knoxdaily.comK

Why Is OncoSec Medical (ONCS) Stock Up 100% Today?

June 23, 2023 | markets.businessinsider.com

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

June 15, 2023 | msn.com

Why Is OncoSec Medical (ONCS) Stock Down 48% Today?

June 15, 2023 | msn.com

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 18, 2023 | finance.yahoo.com

OncoSec Medical plunges 35% lower on sale of 1.4M shares of common stock

May 16, 2023 | msn.com

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 16, 2023 | finance.yahoo.com

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

May 16, 2023 | finance.yahoo.com

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

April 27, 2023 | finance.yahoo.com

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 11, 2023 | finance.yahoo.com

Why OncoSec Medical Shares Are Soaring Today

April 10, 2023 | msn.com

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 10, 2023 | finance.yahoo.com

OncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Trading

April 6, 2023 | benzinga.com

OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study

April 3, 2023 | finance.yahoo.com

OncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trial

April 3, 2023 | msn.com

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

April 3, 2023 | finance.yahoo.com

OncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%

March 1, 2023 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCS, ADIL, KLDO, and NMTR Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.40 +0.01 (+1.27%)

As of 02:13 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Kaleido Biosciences NASDAQ:KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

OncoSec Medical NASDAQ:ONCS

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time